Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. has demonstrated strong performance in its advanced wound care product segment, particularly with Apligraf, which boasts an effective average selling price (ASP) that is four times higher than previous levels, positioning it as a competitive leader based on efficacy. Despite facing market volatility related to reimbursement structures, the company is experiencing monthly and daily increases in unit volumes, suggesting a potential trajectory for growth in future quarters. Additionally, the approved reimbursement rate of $127.28 per square centimeter for CY2026, which is slightly higher than previously proposed, reflects a favorable outlook for financial performance and may enhance the company's valuation significantly.

Bears say

Organogenesis Holdings Inc. has faced a significant share price decline of approximately 35% due to softer-than-expected fiscal year 2026 guidance, primarily attributed to reimbursement changes in the Advanced Wound Care market. The company anticipates a substantial 50% year-over-year decline in the first quarter of 2026, driven by the need to address product sizing waste and excess inventory. Furthermore, risks are compounded by potential issues such as lower-than-expected growth of its PuraPly product, regulatory hurdles, and challenges posed by Medicare pricing policies, leading to diminished confidence in future financial performance.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.